[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"d56691d6-631f-4daa-9d9c-1b3527ec47af","acronym":"SAFE ESO","url":"https://clinicaltrials.gov/study/NCT07205731","created_at":"2025-10-11T01:29:40.189Z","updated_at":"2025-10-11T01:29:40.189Z","phase":"Phase 2","brief_title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","source_id_and_acronym":"NCT07205731 - SAFE ESO","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-10-03"},{"id":"716dc364-32b8-4cd4-ad8c-813b9359535b","acronym":"PB-PD1R-SCC","url":"https://clinicaltrials.gov/study/NCT07147361","created_at":"2025-09-07T01:05:27.471Z","updated_at":"2025-09-07T01:05:27.471Z","phase":"","brief_title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","source_id_and_acronym":"NCT07147361 - PB-PD1R-SCC","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-08-29"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"69599cf2-202e-4fe7-9acb-d62f0391eb96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06248411","created_at":"2024-02-08T19:21:09.867Z","updated_at":"2025-02-25T16:47:25.816Z","phase":"Phase 1","brief_title":"A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06248411","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 10/31/2029","primary_completion_date":" 10/31/2029","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2025-02-05"},{"id":"b338379e-ef5a-43a2-a2ae-225d86a98ac0","acronym":"AdvanTIG-203","url":"https://clinicaltrials.gov/study/NCT04732494","created_at":"2021-02-01T16:58:08.345Z","updated_at":"2025-02-25T17:30:34.219Z","phase":"Phase 2","brief_title":"Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT04732494 - AdvanTIG-203","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/26/2023","study_completion_date":" 12/26/2023","last_update_posted":"2025-01-31"},{"id":"69217ac1-4fa4-4e9f-9c24-69f00b5e6dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05937438","created_at":"2023-07-10T13:08:45.201Z","updated_at":"2025-02-25T17:39:00.933Z","phase":"Phase 1/2","brief_title":"Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma","source_id_and_acronym":"NCT05937438","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-29"},{"id":"84d273e3-f912-4f66-80af-054c9469875c","acronym":"TROPION-PanTumor01","url":"https://clinicaltrials.gov/study/NCT03401385","created_at":"2021-01-18T16:47:07.204Z","updated_at":"2025-02-25T14:58:37.689Z","phase":"Phase 1","brief_title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","source_id_and_acronym":"NCT03401385 - TROPION-PanTumor01","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-03"},{"id":"7ea36563-78f7-472c-9677-af2100aca055","acronym":"","url":"https://clinicaltrials.gov/study/NCT06665776","created_at":"2025-02-26T11:55:39.385Z","updated_at":"2025-02-26T11:55:39.385Z","phase":"","brief_title":"HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan","source_id_and_acronym":"NCT06665776","lead_sponsor":"PharmaEssentia","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-25"},{"id":"9a4cccf9-473c-4823-accb-9c31a88dc9d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06675201","created_at":"2025-02-26T15:23:40.675Z","updated_at":"2025-02-26T15:23:40.675Z","phase":"Phase 2","brief_title":"Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06675201","lead_sponsor":"Sichuan University","biomarkers":" PD-L1 • TMB","pipe":"","alterations":" ","tags":["PD-L1 • TMB"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-11-05"},{"id":"4f96feb5-50d1-43c3-856c-1a2c5c1c2a65","acronym":"ESCC","url":"https://clinicaltrials.gov/study/NCT06601309","created_at":"2025-02-26T07:12:45.028Z","updated_at":"2025-02-26T07:12:45.028Z","phase":"Phase 2","brief_title":"Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC","source_id_and_acronym":"NCT06601309 - ESCC","lead_sponsor":"Fujian Medical University Union Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/11/2024","start_date":" 07/11/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-19"},{"id":"a9b98e89-64a8-4245-99e7-c014eaeac52a","acronym":"KEYNOTE-B59","url":"https://clinicaltrials.gov/study/NCT04977453","created_at":"2024-02-20T21:30:41.481Z","updated_at":"2025-02-25T16:16:30.492Z","phase":"Phase 1/2","brief_title":"GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04977453 - KEYNOTE-B59","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-19"},{"id":"6206800b-ada7-4d44-b7fb-032aa56563fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084481","created_at":"2023-10-16T15:12:52.682Z","updated_at":"2024-07-02T16:34:26.033Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","source_id_and_acronym":"NCT06084481","lead_sponsor":"AbbVie","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 11/09/2023","start_date":" 11/09/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-14"},{"id":"f9f357c2-8949-408a-8e82-24a82b424f06","acronym":"EVER-132-003","url":"https://clinicaltrials.gov/study/NCT05119907","created_at":"2023-03-03T17:01:47.232Z","updated_at":"2024-07-02T16:34:25.825Z","phase":"Phase 2","brief_title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","source_id_and_acronym":"NCT05119907 - EVER-132-003","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"b14ae2ce-d6cf-4d4b-a89a-5b7b74713803","acronym":"KEYNOTE-590","url":"https://clinicaltrials.gov/study/NCT03189719","created_at":"2021-01-17T17:21:07.791Z","updated_at":"2024-07-02T16:34:27.018Z","phase":"Phase 3","brief_title":"First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)","source_id_and_acronym":"NCT03189719 - KEYNOTE-590","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil"],"overall_status":"Completed","enrollment":" Enrollment 749","initiation":"Initiation: 07/25/2017","start_date":" 07/25/2017","primary_txt":" Primary completion: 07/02/2020","primary_completion_date":" 07/02/2020","study_txt":" Completion: 07/10/2023","study_completion_date":" 07/10/2023","last_update_posted":"2024-06-12"},{"id":"144bc660-3c94-4a69-b174-23b147056c11","acronym":"","url":"https://clinicaltrials.gov/study/NCT06342167","created_at":"2024-04-02T18:41:55.615Z","updated_at":"2024-07-02T16:34:27.054Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06342167","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/14/2024","start_date":" 03/14/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-11"},{"id":"1b39475a-c778-482c-b273-baa5f64197c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114319","created_at":"2021-01-18T15:21:08.086Z","updated_at":"2024-07-02T16:34:59.273Z","phase":"Phase 1","brief_title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03114319","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e batoprotafib (TNO155) • nazartinib (EGF816)"],"overall_status":"Recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 06/11/2025","primary_completion_date":" 06/11/2025","study_txt":" Completion: 06/11/2025","study_completion_date":" 06/11/2025","last_update_posted":"2024-06-04"},{"id":"627558e9-c3d7-4f51-90e5-5a44fbbddb52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351103","created_at":"2021-01-18T05:31:16.537Z","updated_at":"2024-07-02T16:34:59.934Z","phase":"Phase 1","brief_title":"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","source_id_and_acronym":"NCT01351103","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF • RNF43","pipe":" | ","alterations":" BRAF mutation • RNF43 mutation","tags":["BRAF • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • WNT974"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2024-05-30"},{"id":"ef5b7233-6e30-4c45-b394-e075f2b99639","acronym":"","url":"https://clinicaltrials.gov/study/NCT04192695","created_at":"2021-01-18T20:25:59.272Z","updated_at":"2024-07-02T16:35:04.946Z","phase":"","brief_title":"Esophageal Squamous Cell Cancer Surveillance With Cytosponge","source_id_and_acronym":"NCT04192695","lead_sponsor":"Centre of Postgraduate Medical Education","biomarkers":" TP53 • NFE2L2 • CHN1","pipe":"","alterations":" ","tags":["TP53 • NFE2L2 • CHN1"],"overall_status":"Completed","enrollment":" Enrollment 178","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-05-08"},{"id":"1afa5b67-0ab9-48e8-b708-cf6daee5469f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06034860","created_at":"2023-09-13T14:09:53.369Z","updated_at":"2024-07-02T16:35:06.666Z","phase":"Phase 1","brief_title":"Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types","source_id_and_acronym":"NCT06034860","lead_sponsor":"Molecular Templates, Inc.","biomarkers":" PD-L1 • MSI • PD-1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • MT-8421"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-01"},{"id":"6b25190a-451d-47e6-90b5-2c15cef6b530","acronym":"","url":"https://clinicaltrials.gov/study/NCT04730843","created_at":"2021-01-29T12:55:15.412Z","updated_at":"2024-07-02T16:35:07.355Z","phase":"Phase 1","brief_title":"A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04730843","lead_sponsor":"Elpiscience Biopharma, Ltd.","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ordastobart (INBRX-106)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-04-26"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"}]